CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization